Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

135 hip patients watched for 10 years to see how implant holds up

NCT ID NCT04122157

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 135 people who received a specific type of hip replacement implant (SL-PLUS MIA stem) for up to 10 years. The goal was to see how long the implant lasts, check for problems like loosening or infection, and track X-ray changes. Participants had standard follow-up care, and no extra treatments were given. The study helps doctors understand the implant's long-term performance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

135 people

The number who actually took part.

Started

Jul 2007

Finished

Nov 2019

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

135 consecutive cases (uncoated SL-PLUS® MIA implants)

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with primary or secondary hip osteoarthritis * Patients scheduled for a first implantation * Age at the time of surgery 40-80 years Exclusion Criteria: * Destruction of the acetabulum * Deformation of the hip joint * Deformation of the proximal femur * Revision of failed hip endoprostheses * Acute or recent infection of the joint or its surrounding region * Acute or chronic systemic infections * Marked atrophy or deformation of the upper femur * Muscle atrophy or a neuromuscular disease * Pathological fractures * Per- to subtrochanteric fractures * Conditions that would prevent secure anchoring of the hip prosthesis * Obese patients with a BMI \>35 * Patients not expected to have a successful rehabilitation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hip osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.